title: Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy.
abstract: Combination antiretroviral therapy (cART) reduced the incidence of Kaposi's Sarcoma (KS), mainly mediated by the suppression of HIV replication and the recovery of the immune system. The effect of specific classes of antiretrovirals on KS remains unclear. However, both in vitro and clinical studies provided evidences that protease inhibitors (PI) can inhibit Human Herpesvirus 8 (HHV-8) replication and reduce KS risk and progression. Moreover, relapses of KS in HIV-infected patients switching from a PI to a non-nucleoside reverse transcriptase inhibitor-based cART have been reported. We describe here the case of a patient who experienced a relapse of KS and a rebound of HHV-8 viremia two months after switching from a PI to an integrase inhibitor-based cART.
authors.affiliation: Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.
authors.forename: Francesco Roberto
authors.initials: FR
authors.lastname: Simonetti
authors.affiliation: Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Ricaboni
authors.affiliation: Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Cattaneo
authors.affiliation: Clinical Microbiology Virology and Diagnosis of Bioemergency, L. Sacco University Hospital, Milan, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Micheli
authors.affiliation: Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Rusconi
authors.affiliation: 3rd Division of Infectious Diseases, L. Sacco University Hospital, Via GB Grassi 74, 20157 Milan, Italy. Electronic address: cristina.gervasoni@unimi.it.
authors.forename: Cristina
authors.initials: C
authors.lastname: Gervasoni
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D019429:Integrase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000008:administration & dosage*; D012008:Recurrence; D012514:Sarcoma, Kaposi / Q000175:diagnosis* / Q000821:virology; D014766:Viremia / Q000175:diagnosis*
chemical_list: D044966:Anti-Retroviral Agents; D019429:Integrase Inhibitors; D011480:Protease Inhibitors
keywords: HHV-8; HIV; Integrase inhibitors; Kaposi’s Sarcoma; Protease inhibitors